EGFR and non-small cell lung carcinoma: Therapeutic restoration of miR-145 via nanoparticle delivery has shown promise in preclinical models, reducing invasion by >60% and resensitizing tumors to EGFR inhibitors, positioning it as a compelling target for RNA-based therapies in NSCLC.